BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 30454647)

  • 1. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
    Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
    Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2.
    Gurzov EN; Tran M; Fernandez-Rojo MA; Merry TL; Zhang X; Xu Y; Fukushima A; Waters MJ; Watt MJ; Andrikopoulos S; Neel BG; Tiganis T
    Cell Metab; 2014 Jul; 20(1):85-102. PubMed ID: 24954415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 7. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
    J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of FGF21 promotes NASH-HCC transition
    Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
    Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
    [No Abstract]   [Full Text] [Related]  

  • 11. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    Wang X; Zeldin S; Shi H; Zhu C; Saito Y; Corey KE; Osganian SA; Remotti HE; Verna EC; Pajvani UB; Schwabe RF; Tabas I
    J Hepatol; 2022 Apr; 76(4):910-920. PubMed ID: 34902531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1.
    Gallage S; Ali A; Barragan Avila JE; Seymen N; Ramadori P; Joerke V; Zizmare L; Aicher D; Gopalsamy IK; Fong W; Kosla J; Focaccia E; Li X; Yousuf S; Sijmonsma T; Rahbari M; Kommoss KS; Billeter A; Prokosch S; Rothermel U; Mueller F; Hetzer J; Heide D; Schinkel B; Machauer T; Pichler B; Malek NP; Longerich T; Roth S; Rose AJ; Schwenck J; Trautwein C; Karimi MM; Heikenwalder M
    Cell Metab; 2024 Jun; 36(6):1371-1393.e7. PubMed ID: 38718791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Obesogenic Dietary Mouse Model of Nonalcoholic Steatohepatitis.
    Zarrouki B; Boucher J
    Methods Mol Biol; 2020; 2164():121-127. PubMed ID: 32607889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
    J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
    Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
    Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
    Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
    Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
    Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
    Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.